Wire · opportunities
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
Latigo Biotherapeutics completed an upsized IPO raising $397.4 million to fund operations into 2029, published positive Phase 2 clinical results for onzotrigine in acute pain in The New England Journal of Medicine, and appointed former FDA deputy director Naomi Lowy as senior VP of global regulatory affairs.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must recognise that regulatory expertise like Naomi Lowy’s onboard accelerates your drug’s path to market by smoothing FDA approval for non-opioid pain treatments. The clear clinical progress with onzotrigine funds a strategic launch window before 2029—prepare your commercial and development partnerships now.
◆ Coverage
1 source · 3 Sep 2026
◆ Related on Wire
◆ Topics